William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on October 31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight PTC Therapeutics’ strong market position and growth potential. The impressive launch of Sephience, which has seen robust demand among both prescribers and patients, is a key driver for this positive outlook. The drug’s rapid efficacy and broad utility suggest it could become the new standard of care for PKU patients, significantly contributing to the company’s revenue and future cash flow positivity.
Additionally, upcoming milestones such as regulatory meetings and international launches are expected to act as catalysts for the stock’s performance. While there is some caution regarding the potential approval of Translarna and vatiquinone in the U.S., the narrowed revenue guidance reflects confidence in maintaining market share for Emflaza despite generic competition. The strong third-quarter earnings, driven by Sephience’s uptake, further support the Buy rating, with revenue surpassing both estimates and consensus.
Corwin covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, Solid Biosciences, and Kyverna Therapeutics, Inc.. According to TipRanks, Corwin has an average return of 25.7% and a 54.82% success rate on recommended stocks.
In another report released on October 31, Truist Financial also maintained a Buy rating on the stock with a $86.00 price target.